Edition:
India

Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise


Friday, 20 Oct 2017 

Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​.Aurinia Pharmaceuticals - ‍ plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES.Aurinia Pharmaceuticals - ‍a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018​. 

Latest Developments forAurinia Pharmaceuticals Inc

Company Quote

6.06
-0.11 -1.78%
20 Sep 2019